Sage Therapeutics Inc. (NASDAQ:SAGE) saw an uptick in trading volume on Tuesday . 1,391,954 shares traded hands during mid-day trading, an increase of 65% from the previous session’s volume of 845,709 shares.The stock last traded at $37.41 and had previously closed at $42.46.

A number of brokerages have recently commented on SAGE. Canaccord Genuity reissued a “buy” rating and issued a $110.00 target price on shares of Sage Therapeutics in a research note on Sunday, May 8th. Leerink Swann reaffirmed a “buy” rating and set a $66.00 price target on shares of Sage Therapeutics in a research note on Tuesday, July 12th. Cowen and Company reaffirmed a “buy” rating on shares of Sage Therapeutics in a research note on Tuesday, July 12th. BMO Capital Markets reaffirmed a “buy” rating on shares of Sage Therapeutics in a research note on Tuesday, July 12th. Finally, Chardan Capital initiated coverage on shares of Sage Therapeutics in a research note on Tuesday, May 24th. They set a “sell” rating and a $18.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $66.18.

The company’s market capitalization is $1.18 billion. The firm has a 50-day moving average of $38.13 and a 200 day moving average of $34.58.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($1.08) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.02) by $0.06. On average, equities research analysts predict that Sage Therapeutics Inc. will post ($4.30) earnings per share for the current year.

In other Sage Therapeutics news, Director Kevin P. Starr sold 850,000 shares of the business’s stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $31.25, for a total value of $26,562,500.00. Following the completion of the sale, the director now directly owns 65,227 shares of the company’s stock, valued at $2,038,343.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Albert Robichaud sold 22,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 12th. The stock was sold at an average price of $40.00, for a total transaction of $880,000.00. Following the completion of the sale, the insider now directly owns 140,222 shares of the company’s stock, valued at $5,608,880. The disclosure for this sale can be found here.

Other hedge funds have bought and sold shares of the company. Nationwide Fund Advisors increased its stake in Sage Therapeutics by 9.4% in the fourth quarter. Nationwide Fund Advisors now owns 21,143 shares of the biopharmaceutical company’s stock valued at $1,233,000 after buying an additional 1,816 shares in the last quarter. California State Teachers Retirement System increased its stake in Sage Therapeutics by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 25,578 shares of the biopharmaceutical company’s stock valued at $1,491,000 after buying an additional 400 shares in the last quarter. Marshall Wace LLP acquired a new stake in Sage Therapeutics during the fourth quarter valued at approximately $1,870,000. Jennison Associates LLC acquired a new stake in Sage Therapeutics during the fourth quarter valued at approximately $14,875,000. Finally, RS Investment Management Co. LLC increased its stake in Sage Therapeutics by 14.7% in the fourth quarter. RS Investment Management Co. LLC now owns 504,405 shares of the biopharmaceutical company’s stock valued at $29,407,000 after buying an additional 64,567 shares in the last quarter.

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.